Anti-Mouse CD120b (TNFR2) (Clone TR75-54.7) – Purified in vivo PLATINUM™ Functional Grade

Purified Recombinant Mouse TNF R2

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

IP
B
WB
ELISA Cap

Anti-Mouse CD120 recognizes Mouse CD120. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Tumor necrosis factor receptor II (TNF-RII) is present on most cell types¹ and is considered to play a prominent role in stimulation by TNF-alpha. TNFRII proteins are expressed by hematopoietic cells including macrophages, neutrophils, lymphocytes, thymocytes and mast cells. It is expressed by a variety of other cell types including endothelial cells, cardiac myocytes and prostate cells.²

Variety of cell types at low levels

TNF-α, LT-α (TNF-β)

Apoptosis, NF-κB activation, inflammation, tumor necrosis, cell differentiation

1. Zuckerman, KS. et al. (1998) Cancer Res. 58:2217.
2. Sheehan, KC. et al. (1995) J. Exp. Med. 181:607.